
About SMT
SMT is a publicly listed company based in Surat (India) founded in 1998. SMT is recognized as a developer of cardiovascular medical devices. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 1,090 employees. SMT has completed 2 acquisitions, including Vascular Concepts and Zarek. SMT was last valued at $329.92 million in January 2023. Its chief executive, as recorded, is Bhargav Kotadia. Its website smtpl.com draws about 13 thousand monthly visits. Its Indian entity Sahajanand Medical Technologies Limited reported revenue of βΉ1,219 Cr. SMT offers products and services including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit. Its focus areas include Medical Devices and Cardiovascular Devices.
Company details
SMT, officially known as Sahajanand Medical Technologies Ltd., is engaged in the development and manufacturing of minimally invasive cardiovascular devices. The company operates within the healthcare sector, focusing on coronary stents, structural heart devices, and peripheral intervention solutions. Products such as Supraflex Cruz and Hydra Aortic Valve are designed to address conditions like coronary artery disease and aortic stenosis. With a global presence, SMT is committed to advancing patient care through innovative medical solutions across multiple regions.
- Market Cap₹5,522 Cr
SMT · NSE
- Share Price₹550.00
+1.24% today
- Revenue₹1,210 Cr
FY 2025-26 · +15.3% YoY
- EBITDA₹171 Cr
Margin 14.1%
- Net Profit₹65.27 Cr
FY 2025-26 · +170.2% YoY
- P/E (TTM)82.8x
P/B 7.8x
- ROE10.9%
ROCE 11.4%
- Debt / Equity0.44
Interest cover 25.3x
- Latest Funding Round$20.87M (USD), Unspecified
Jan 2023
- InvestorsSBI Mutual Fund
& 78 more
- Employee Count1,090
- Investments & AcquisitionsVascular Concepts
& 1 more
Associated legal entities of SMT
SMT operates through Sahajanand Medical Technologies Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sahajanand Medical Technologies Limited Listed CIN U33119GJ2001PLC040121 | Active | 18 Oct 2001 | Surat, Gujarat | ₹1,219 Cr | 1,090 | 11 | View details |
Products & Services of SMT
SMT offers a comprehensive portfolio of products and services, including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.
Advanced coronary stent used for arterial blockages treatment.
Valve designed for treating severe aortic stenosis conditions.
Device used to close atrial septal heart defects.
Balloon expandable stent for renal and biliary issues.
Apps and channels of SMT
its YouTube channel SMT has 528 subscribers and 30 videos.
Videos from SMT
The most watched videos on SMT's YouTube channel, SMT (528 subscribers). Click a video to play it here.
More on SMT.
Funding Insights of SMT
- Total Rounds 4
- Last Round Unspecified β $20.87M
- First Round $35,130
(Mar 2009)
- Investors Count 79
All 4 funding rounds of SMT with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $20.87M | Unspecified | $329.92M | Kotak Mahindra Bank | β |
| Jan 2022 | $11.09M | Unspecified | $309.22M | SBI Mutual Fund | |
| Dec 2016 | $25.22M | Unspecified | β | Samara Capital | β |
| Mar 2009 | $35,130 | Unspecified | $β’β’β’β’β’ | Rahul Gaywala |
| Date | Valuation | Stage |
|---|---|---|
| Jan 2023 | $329.92M | β’β’β’β’β’β’β’β’ |
| Jan 2022 | $309.22M | β’β’β’β’β’β’β’β’ |
| Mar 2009 | $β’β’β’β’β’ | β’β’β’β’β’β’β’β’ |
Full valuation and stage history of SMT
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $329.92M (Jan 2023). 79 investors in total: 4 institutional and 75 angel.
Investors in SMT
SMT has secured backing from 79 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, Kotak Mahindra Bank and Plutus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are managed across multiple sectors. | samaracapital.com | Mumbai, India | ||
Commercial banking services are offered to corporate and retail customers. | 1985 | kotak.com | Mumbai, India | |
Provides mutual funds management and financial advisory services. | 1987 | sbimf.com | Mumbai, India | |
Financial planning and investment management services are provided by Plutus. | plutuswealth.com | London, United Kingdom | ||
MM Madhuri Madhusudan Kela | unknown_75cab185e2a04d0e8 | |||
MB Martin B Leon | unknown_3bcdec058a924c94b | |||
DD Debojyoti Dutta | unknown_117f06fafcf64a569 | |||
SN Sriram Nadathar | unknown_b5262fdc2b2547d48 | |||
AM Alka Manoj Rabadiya | unknown_2039a3a702834e328 | |||
AK Ashit Kumar Sanghrajka | unknown_e253a2306b5a40048 |
Investor details for SMT
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sahajanand Medical Technologies Limited (SMT)
Sahajanand Medical Technologies Limited is the primary company behind SMT. The board of Sahajanand Medical Technologies Limited currently have 8 directors; the longest-serving is Dhirajlal Vallabhbhai Kotadia, appointed in 2004. 27 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Dhirajlal Vallabhbhai Kotadia DIN 00013035 | Director | 25 Mar 2004 | 22 yrs 7 mo | Sahajanand Medical Technologies Limited |
| Bhargav Dhirajlal Kotadia DIN 06575042 | Managing Director | 06 May 2013 | 13 yrs 6 mo | Sahajanand Medical Technologies Limited |
| Abhishek Rajendrakumar Kabra DIN 06782685 | Director | 28 Dec 2016 | 9 yrs 10 mo | Sahajanand Medical Technologies Limited |
| Jose Calle Gordo DIN 08568779 | Director | 20 Sep 2019 | 7 yrs 1 mo | Sahajanand Medical Technologies Limited |
| Sonalika Dhar DIN 10221436 | Director | 30 Jun 2023 | 3 yrs 4 mo | Sahajanand Medical Technologies Limited |
| Debasis Panigrahi DIN 08838872 | Director | 22 Sep 2023 | 3 yrs 1 mo | Sahajanand Medical Technologies Limited |
| Harvinder Pal Singh DIN 10416949 | Director | 01 Jul 2025 | 1 yr 4 mo | Sahajanand Medical Technologies Limited |
| Priyanka Dhirajlal Cohen DIN 11181810 | Director | 03 Jul 2025 | 1 yr 4 mo | Sahajanand Medical Technologies Limited |
People of SMT
3 people are tracked at SMT (3 in leadership); the tracked headcount is 1,090.
| Name | Role | Group |
|---|---|---|
| CEO & MD | Leadership | |
| Chief Executive Officer | Leadership | |
Gaurav Goel | CCO | Leadership |
Complete people profiles for SMT
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SMT
SMT is a publicly listed company on the NSE with ticker symbol SMT in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNSE: SMT
- Listed entitySahajanand Medical Technologies Limited
Financials of SMT
Exchange-reported figures of Sahajanand Medical Technologies Limited, the listed company behind SMT (NSE: SMT).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 1,210 | 1,050 | 954 | 690 | 589 |
| Revenue growth | +15.3% | +10.0% | - | +17.2% | - |
| EBITDA | 171 | 113 | 110 | 32.39 | 7.06 |
| EBITDA margin | +14.1% | +10.8% | +11.5% | +4.7% | +1.2% |
| Profit before tax | 80.28 | 40.81 | 33.09 | (30.38) | (45.29) |
| Net profit | 65.27 | 24.16 | (12.83) | (47.95) | (49.01) |
| Net profit margin | +5.4% | +2.3% | -1.3% | -7.0% | -8.3% |
| EPS (βΉ) | 6.48 | 2.09 | (1.31) | (5.49) | (8.14) |
| Balance sheet | |||||
| Total assets | 1,019 | 855 | 774 | 826 | 685 |
| Net worth | 695 | 566 | 540 | 401 | 334 |
| Total debt | 306 | 254 | 201 | 386 | 325 |
| Cash & bank | 75.49 | 102 | 73.53 | 174 | 144 |
| Net working capital | 518 | 456 | 396 | 460 | 405 |
| Cash flow | |||||
| Cash from operations | 105 | 73.52 | 41.10 | 16.84 | 46.35 |
| Cash from investing | (120) | (50.44) | (41.80) | (154) | (169) |
| Cash from financing | (12.04) | 5.77 | 13.13 | 109 | 212 |
| Particulars | Sep 2026 | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 373 | 352 | 299 | 281 |
| Revenue growth (YoY) | +24.7% | +25.2% | - | - |
| Other income | 2.24 | 2.67 | 2.34 | 3.16 |
| EBITDA | 65.55 | 48.58 | 47.97 | 31.63 |
| EBITDA margin | +17.6% | +13.8% | +16.0% | +11.3% |
| Depreciation | 20.91 | 20.41 | 17.22 | 16.17 |
| Interest | 6.81 | 6.55 | 6.01 | 5.78 |
| Profit before tax | 40.07 | 24.29 | 27.08 | 12.84 |
| Tax | 13.60 | 9.20 | 6.18 | (4.91) |
| Net profit | 26.47 | 15.09 | 20.90 | 17.75 |
| EPS (βΉ) | 2.56 | 1.45 | 1.94 | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 551 | 530 | 509 | 457 | 439 | 403 |
| Revenue growth | +3.9% | +4.2% | +11.2% | +4.1% | +9.1% | - |
| EBITDA | 77.92 | 16.05 | 21.12 | 56.84 | 24.58 | 22.91 |
| EBITDA margin | +14.1% | +3.0% | +4.2% | +12.4% | +5.6% | +5.7% |
| Profit before tax | 46.05 | (3.29) | (3.86) | 34.17 | 12.62 | 15.22 |
| Net profit | 42.34 | (2.19) | (35.08) | 20.70 | (6.60) | (13.27) |
| Net profit margin | +7.7% | -0.4% | -6.9% | +4.5% | -1.5% | -3.3% |
| EPS (βΉ) | 4.43 | (0.81) | (3.54) | 2.13 | (0.10) | (1.16) |
| Balance sheet | ||||||
| Total assets | 891 | 802 | 725 | 732 | 592 | 462 |
| Net worth | 677 | 622 | 631 | 688 | 534 | 430 |
| Total debt | 211 | 175 | 90.38 | 40.68 | 49.62 | 26.63 |
| Cash & bank | 6.47 | 36.41 | 12.24 | 8.22 | 119 | 32.69 |
| Net working capital | 195 | 152 | 132 | 183 | 318 | 219 |
| Cash flow | ||||||
| Cash from operations | 8.43 | 11.77 | 25.62 | 74.53 | 34.02 | 105 |
| Cash from investing | (52.25) | (50.77) | (57.92) | (198) | (91.01) | (55.66) |
| Cash from financing | 13.99 | 63.15 | 31.27 | 94.70 | 82.96 | (55.09) |
| Particulars | Sep 2026 | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 159 | 153 | 135 | 123 |
| Revenue growth (YoY) | +17.5% | +24.2% | - | - |
| Other income | 1.95 | 1.40 | 1.73 | 1.70 |
| Total expenses | 138 | 133 | 112 | 115 |
| EBITDA | 20.40 | 20.51 | 23.40 | 8.17 |
| EBITDA margin | +12.9% | +13.4% | +17.3% | +6.6% |
| Depreciation | 5.07 | 4.74 | 5.08 | 4.62 |
| Interest | 4.23 | 4.16 | 4.67 | 3.79 |
| Profit before tax | 13.05 | 13.01 | 15.38 | 1.46 |
| Tax | 3.22 | 3.69 | 3.18 | (8.15) |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 373 | 352 | 299 | 281 |
| Revenue growth (YoY) | +24.7% | +25.2% | - | - |
| Other income | 2.24 | 2.67 | 2.34 | 3.16 |
| EBITDA | 65.55 | 48.58 | 47.97 | 31.63 |
| EBITDA margin | +17.6% | +13.8% | +16.0% | +11.3% |
| Depreciation | 20.91 | 20.41 | 17.22 | 16.17 |
| Interest | 6.81 | 6.55 | 6.01 | 5.78 |
| Profit before tax | 40.07 | 24.29 | 27.08 | 12.84 |
| Tax | 13.60 | 9.20 | 6.18 | (4.91) |
| Net profit | 26.47 | 15.09 | 20.90 | 17.75 |
| EPS (βΉ) | 2.56 | 1.45 | 1.94 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Revenue | 1,210 | 1,050 | 954 | 690 | 589 |
| Revenue growth | +15.3% | +10.0% | - | +17.2% | - |
| Other income | 8.22 | 11.08 | 6.99 | (2.79) | 3.44 |
| Total expenses | 1,040 | 937 | 844 | 657 | 581 |
| Employee cost | 0.00 | 292 | 254 | 193 | 136 |
| EBITDA | 171 | 113 | 110 | 32.39 | 7.06 |
| EBITDA margin | +14.1% | +10.8% | +11.5% | +4.7% | +1.2% |
| Depreciation | 74.16 | 62.53 | 64.50 | 37.74 | 35.42 |
| Interest | 24.43 | 20.73 | 19.44 | 22.24 | 20.37 |
| Profit before tax | 80.28 | 40.81 | 33.09 | (30.38) | (45.29) |
| Tax | 11.21 | 15.66 | 40.45 | 18.41 | 27.05 |
| Net profit | 65.27 | 24.16 | (12.83) | (47.95) | (49.01) |
| Net profit margin | +5.4% | +2.3% | -1.3% | -7.0% | -8.3% |
| EPS (βΉ) | 6.48 | 2.09 | (1.31) | (5.49) | (8.14) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Equity & liabilities | |||||
| Share capital | 9.81 | 9.77 | 9.75 | 9.24 | 8.89 |
| Reserves & surplus | 686 | 556 | 530 | 392 | 325 |
| Shareholders' funds (net worth) | 695 | 566 | 540 | 401 | 334 |
| Minority interest | 6.83 | 24.74 | 26.23 | 18.02 | 12.93 |
| Secured loans | 244 | 182 | 161 | 368 | 278 |
| Unsecured loans | 62.27 | 71.38 | 39.62 | 17.69 | 47.35 |
| Total debt | 306 | 254 | 201 | 386 | 325 |
| Total liabilities | 1,019 | 855 | 774 | 826 | 685 |
| Assets | |||||
| Gross block | 672 | 540 | 498 | 290 | 263 |
| Net block | 343 | 288 | 296 | 207 | 203 |
| Capital work in progress | 9.01 | 6.31 | 13.44 | 122 | 59.81 |
| Investments | 58.55 | 4.92 | 6.30 | 0.00 | 0.00 |
| Inventories | 309 | 267 | 252 | 160 | 143 |
| Sundry debtors | 286 | 263 | 215 | 236 | 255 |
| Cash & bank balances | 75.49 | 102 | 73.53 | 174 | 144 |
| Loans & advances | 102 | 61.62 | 49.14 | 62.31 | 24.82 |
| Total current assets | 773 | 694 | 590 | 633 | 567 |
| Total current liabilities | 255 | 238 | 194 | 173 | 162 |
| Net working capital | 518 | 456 | 396 | 460 | 405 |
| Total assets | 1,019 | 855 | 774 | 826 | 685 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Opening cash | 101 | 71.67 | 59.24 | 112 | 22.99 |
| Net cash from operating activities | 105 | 73.52 | 41.10 | 16.84 | 46.35 |
| Net cash from investing activities | (120) | (50.44) | (41.80) | (154) | (169) |
| Net cash from financing activities | (12.04) | 5.77 | 13.13 | 109 | 212 |
| Net change in cash | (26.43) | 28.85 | 12.43 | (28.69) | 89.08 |
| Closing cash | 75.49 | 102 | 73.53 | 174 | 144 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Growth | |||||
| Sales growth | +15.3% | +10.0% | - | +17.2% | - |
| EBITDA growth | +51.0% | +2.7% | - | +358.8% | - |
| PBT growth | +96.8% | +23.3% | +9998.0% | +32.9% | +9997.0% |
| Net income growth | +170.2% | +288.3% | - | +2.2% | - |
| Revenue CAGR (3Y) | +20.6% | +20.3% | - | - | - |
| EBITDA CAGR (3Y) | +74.0% | +152.0% | - | - | - |
| Profitability & leverage | |||||
| Net income margin | +5.7% | +2.5% | -0.8% | -7.1% | -12.3% |
| Return on capital employed | +11.4% | +9.8% | +7.2% | +1.1% | +2.9% |
| Return on net worth | +11.0% | +5.2% | -1.3% | -12.5% | -13.0% |
| Debt / equity | 0.44 | 0.41 | 0.32 | 0.97 | 0.56 |
| Long-term debt / equity | 0.10 | 0.10 | 0.15 | 0.79 | 0.36 |
| Interest cover | 25.32 | 41.10 | 42.69 | -415.70 | -71.83 |
| Efficiency & per share | |||||
| Fixed asset turnover | 2.00 | 1.97 | 2.03 | 2.49 | 2.97 |
| Inventory turnover | 4.20 | 3.95 | 4.19 | 4.55 | 4.55 |
| Debtors turnover | 4.40 | 4.28 | 4.37 | 2.81 | 2.44 |
| EPS (βΉ) | 6.65 | 2.09 | (1.31) | (5.49) | (8.14) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 70.87 | 57.96 | 55.42 | 43.42 | 37.52 |
| Particulars | Sep 2026 | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 159 | 153 | 135 | 123 |
| Revenue growth (YoY) | +17.5% | +24.2% | - | - |
| Other income | 1.95 | 1.40 | 1.73 | 1.70 |
| Total expenses | 138 | 133 | 112 | 115 |
| EBITDA | 20.40 | 20.51 | 23.40 | 8.17 |
| EBITDA margin | +12.9% | +13.4% | +17.3% | +6.6% |
| Depreciation | 5.07 | 4.74 | 5.08 | 4.62 |
| Interest | 4.23 | 4.16 | 4.67 | 3.79 |
| Profit before tax | 13.05 | 13.01 | 15.38 | 1.46 |
| Tax | 3.22 | 3.69 | 3.18 | (8.15) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 551 | 530 | 509 | 457 | 439 | 403 |
| Revenue growth | +3.9% | +4.2% | +11.2% | +4.1% | +9.1% | - |
| Other income | 6.06 | 7.53 | 4.12 | 12.56 | 6.67 | 11.75 |
| Total expenses | 473 | 514 | 488 | 401 | 415 | 380 |
| Employee cost | 151 | 141 | 132 | 110 | 110 | 70.76 |
| EBITDA | 77.92 | 16.05 | 21.12 | 56.84 | 24.58 | 22.91 |
| EBITDA margin | +14.1% | +3.0% | +4.2% | +12.4% | +5.6% | +5.7% |
| Depreciation | 21.19 | 16.50 | 20.60 | 17.51 | 13.18 | 12.79 |
| Interest | 16.74 | 10.37 | 8.50 | 17.72 | 5.45 | 6.65 |
| Profit before tax | 46.05 | (3.29) | (3.86) | 34.17 | 12.62 | 15.22 |
| Tax | 2.55 | 4.62 | 30.59 | 13.45 | 13.53 | 25.56 |
| Net profit | 42.34 | (2.19) | (35.08) | 20.70 | (6.60) | (13.27) |
| Net profit margin | +7.7% | -0.4% | -6.9% | +4.5% | -1.5% | -3.3% |
| EPS (βΉ) | 4.43 | (0.81) | (3.54) | 2.13 | (0.10) | (1.16) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 9.81 | 9.76 | 9.75 | 9.75 | 9.24 | 8.89 |
| Reserves & surplus | 668 | 612 | 621 | 678 | 525 | 421 |
| Shareholders' funds (net worth) | 677 | 622 | 631 | 688 | 534 | 430 |
| Secured loans | 201 | 142 | 80.00 | 35.49 | 49.62 | 26.28 |
| Unsecured loans | 10.78 | 33.16 | 10.38 | 5.19 | 0.00 | 0.35 |
| Total debt | 211 | 175 | 90.38 | 40.68 | 49.62 | 26.63 |
| Total liabilities | 891 | 802 | 725 | 732 | 592 | 462 |
| Assets | ||||||
| Gross block | 187 | 174 | 177 | 122 | 105 | 73.22 |
| Net block | 91.94 | 93.58 | 99.74 | 63.42 | 59.57 | 39.75 |
| Capital work in progress | 3.06 | 3.70 | 1.83 | 1.35 | 0.00 | 5.54 |
| Investments | 502 | 498 | 459 | 417 | 74.78 | 72.48 |
| Inventories | 151 | 139 | 132 | 94.85 | 85.69 | 82.09 |
| Sundry debtors | 117 | 136 | 132 | 171 | 186 | 194 |
| Cash & bank balances | 6.47 | 36.41 | 12.24 | 8.22 | 119 | 32.69 |
| Loans & advances | 120 | 47.15 | 29.56 | 49.48 | 40.52 | 46.38 |
| Total current assets | 394 | 358 | 306 | 323 | 431 | 356 |
| Total current liabilities | 199 | 206 | 174 | 141 | 113 | 137 |
| Net working capital | 195 | 152 | 132 | 183 | 318 | 219 |
| Total assets | 891 | 802 | 725 | 732 | 592 | 462 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 36.25 | 12.10 | 13.13 | 36.03 | 10.06 | 15.36 |
| Net cash from operating activities | 8.43 | 11.77 | 25.62 | 74.53 | 34.02 | 105 |
| Net cash from investing activities | (52.25) | (50.77) | (57.92) | (198) | (91.01) | (55.66) |
| Net cash from financing activities | 13.99 | 63.15 | 31.27 | 94.70 | 82.96 | (55.09) |
| Net change in cash | (29.83) | 24.15 | (1.03) | (28.66) | 25.97 | (5.30) |
| Closing cash | 6.47 | 36.41 | 12.24 | 8.22 | 119 | 32.69 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | +3.9% | +4.2% | +11.2% | +4.1% | +9.1% | - |
| EBITDA growth | +385.5% | -24.0% | -62.8% | +131.2% | +7.3% | - |
| PBT growth | +9998.0% | +14.8% | - | +170.8% | -17.1% | +9997.0% |
| Net income growth | +2033.3% | +93.8% | -269.5% | +413.6% | +50.3% | - |
| Revenue CAGR (3Y) | +6.4% | +6.5% | +8.1% | - | - | - |
| EBITDA CAGR (3Y) | +11.1% | -13.2% | -2.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +7.9% | -1.5% | -6.8% | +4.5% | -0.2% | -2.6% |
| Return on capital employed | +7.4% | +3.1% | +0.6% | +7.8% | +6.2% | +11.5% |
| Return on net worth | +6.7% | -0.4% | -5.3% | +3.4% | -1.4% | -3.1% |
| Debt / equity | 0.30 | 0.21 | 0.10 | 0.07 | 0.08 | 0.12 |
| Long-term debt / equity | 0.05 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest cover | 29.51 | -2,304.44 | 1,634.62 | 45.05 | 47.81 | 65.71 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 3.06 | 3.03 | 3.40 | 4.04 | 4.94 | 5.55 |
| Inventory turnover | 3.81 | 3.92 | 4.49 | 5.07 | 5.24 | 4.81 |
| Debtors turnover | 4.37 | 3.95 | 3.36 | 2.57 | 2.31 | 1.90 |
| EPS (βΉ) | 4.43 | (0.81) | (3.54) | 2.13 | (0.10) | (1.16) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 69.02 | 63.69 | 64.71 | 70.58 | 57.79 | 48.32 |
Investments & Acquisitions by SMT
SMT has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Vascular Concepts and Zarek.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Coronary and peripheral stents are manufactured for arterial disease treatments. | vascularconcepts.com | Halstead, United Kingdom | 1992 | May 2020 | β’β’β’β’ | |
| zarek.com.br | 0 | Oct 2019 | β’β’β’β’ |
Complete acquisition details for SMT
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of SMT
6 dated milestones of SMT across 25 years, from founding to its latest funding, stage changes and deals.
- Founded SMT is founded.
- Funding First funding round of $35K.
- Milestone Reaches Minicorn status.
- Acquisition Acquires Zarek.
- Acquisition Acquires Vascular Concepts.
- Funding Latest funding round, Unspecified, of $20.9M.
Web traffic of SMT
The website of SMT (smtpl.com) receives about 13.4K visits a month.
- Monthly visits13.4K
▼ 37% vs previous month
Websites whose visitors overlap most with SMT. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| myhospitalnow.com | 100% | #757,497 | View details | ||
| masterplan-inc.com | 92% | View details | |||
aiimspatna.org | aiimspatna.org | 92% | β | ||
| medicalfair-india.com | 91% | #1,842,824 | View details | ||
emediahealth.com | emediahealth.com | 61% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for SMT
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Smt
Complete news archive for SMT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SMT
SMT was founded in 1998 and raised its 1st funding round 11 years after it was founded.
SMT is headquartered in Surat, India. It is registered at Surat, Gujarat, India.
Bhargav Kotadia is the CEO of SMT, as recorded in our data.
SMT has 1,090 employees.
The primary company behind SMT, Sahajanand Medical Technologies Limited, reported revenue of βΉ1,219 Cr for FY 2026, up 18% year on year.
SMT, officially known as Sahajanand Medical Technologies Ltd., is engaged in the development and manufacturing of minimally invasive cardiovascular devices. The company operates within the healthcare sector, focusing on coronary stents, structural heart devices, and peripheral intervention solutions. Products such as Supraflex Cruz and Hydra Aortic Valve are designed to address conditions like coronary artery disease and aortic stenosis. With a global presence, SMT is committed to advancing patient care through innovative medical solutions across multiple regions.
SMT offers Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.
Yes, SMT is publicly traded on NSE under the ticker symbol SMT.
SMT has made 2 acquisitions, including Vascular Concepts, and Zarek.
SMT has 79 investors. Key investors include SBI Mutual Fund, Kotak Mahindra Bank, Plutus, Madhuri Madhusudan Kela, and Samara Capital.
The valuation of SMT is $329.92M as of Jan 2023.
SMT operates through Sahajanand Medical Technologies Limited.
